Evidence map›Paper›PMID 29182638›Full record

ArticlePLoS medicine2017

Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.

Sunil S Solomon, Allison M McFall, Gregory M Lucas, Aylur K Srikrishnan, Muniratnam S Kumar, Santhanam Anand, Thomas C Quinn, David D Celentano, Shruti H Mehta

Abstract read
In one paragraph

Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sunil S SolomonJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.ORCID http://orcid.org/0000-0002-3296-1514
Allison M McFallJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID http://orcid.org/0000-0002-1157-2931
Gregory M LucasJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Aylur K SrikrishnanY.R. Gaitonde Centre for AIDS Research and Education, Chennai, India.
Muniratnam S KumarY.R. Gaitonde Centre for AIDS Research and Education, Chennai, India.ORCID http://orcid.org/0000-0002-4821-9218
Santhanam AnandY.R. Gaitonde Centre for AIDS Research and Education, Chennai, India.
Thomas C QuinnJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
David D CelentanoJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Shruti H MehtaJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Strategies to improve the HIV care continuum among key populations in IndiaR01DA041034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2015 to 2021
$6.7M
Integrated Care Clinics for IDUs in India: a cluster randomized trialR01DA032059 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2011 to 2015
$6.3M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Preventing HIV Infection Among MSM in Southern IndiaR01MH089266 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CELENTANO, DAVID D. · 2010 to 2015
$2.9M
Reaching the hardest of the hard-to-reachDP2DA040244 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2023
$2.8M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Investigating the Potential of Respondent-Driven Sampling to Reach Undiagnosed, Out-of-Care HIV-infected People Who Inject DrugsF31DA044046 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MCFALL, ALLISON MARIE · 2017 to 2018
$78k
NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI102623NIDA NIH HHS DP2 DA040244NIDA NIH HHS F31 DA044046NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA032059NIDA NIH HHS R01 DA041034NIMH NIH HHS R01 MH089266
6 · The paper itself

Abstract

backgroundA major barrier to achieving ambitious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of infection among key populations such as men who have sex with men (MSM) and people who inject drugs (PWID). We explored the potential of a strategy routinely used for surveillance in these groups, respondent-driven sampling (RDS), to be used as an intervention to identify HIV- and HCV-infected PWID and MSM who are unaware of their status and those who are viremic across 26 Indian cities at various epidemic stages. METHODS AND

findingsData were collected as part of the baseline assessment of an ongoing cluster-randomized trial. RDS was used to accrue participants at 27 sites (15 PWID sites and 12 MSM sites) selected to reflect varying stages of the HIV epidemic among MSM and PWID in India. A total of 56 seeds recruited a sample of 26,447 persons (approximately 1,000 participants per site) between October 1, 2012, and December 19, 2013. Across MSM sites (n = 11,997), the median age was 25 years and the median number of lifetime male partners was 8. Across PWID sites (n = 14,450), 92.4% were male, the median age was 30 years, and 87.5% reported injection in the prior 6 months. RDS identified 4,051 HIV-infected persons, of whom 2,325 (57.4%) were unaware of their HIV infection and 2,816 (69.5%) were HIV viremic. It also identified 5,777 HCV-infected persons, of whom 5,337 (92.4%) were unaware that they were infected with HCV and 4,728 (81.8%) were viremic. In the overall sample (both MSM and PWID), the prevalence of HIV-infected persons who were unaware of their status increased with sampling depth, from 7.9% in participants recruited in waves 1 through 5 to 12.8% among those recruited in waves 26 and above (p-value for trend < 0.001). The overall detection rate of people unaware of their HIV infection was 0.5 persons per day, and the detection rate of HIV-infected persons with viremia (regardless of their awareness status) was 0.7 per day. The detection rate of HIV viremic individuals was positively associated with underlying HIV prevalence and the prevalence of HIV viremia (linear regression coefficient per 1-percentage-point increase in prevalence: 0.05 and 0.07, respectively). The median detection rate of PWID who were unaware of their HCV infection was 2.5 per day. The cost of identifying 1 unaware HIV-infected individual ranged from US$51 to US$2,072 across PWID sites and from US$189 to US$5,367 across MSM sites. The mean additional cost of identifying 1 unaware HCV-infected PWID was US$13 (site range: US$7-US$140). Limitations of the study include the exclusivity of study sites to India, lack of prior HIV/HCV diagnosis confirmation with clinic records, and lack of cost data from other case-finding approaches commonly used in India.

conclusionsIn this study, RDS was able to rapidly identify at nominal cost a substantial number of unaware and viremic HIV-infected and HCV-infected individuals who were currently not being reached by existing programs and who were at high risk for transmission. Combining RDS (or other network-driven recruitment approaches) with strategies focused on linkage to care, particularly in high-burden settings, may be a viable option for achieving the 90-90-90 targets in key populations in resource-limited settings.

Indexed as

AdultCommunity-Based Participatory ResearchCommunity-Institutional RelationsCross-Sectional StudiesHepacivirusHepatitis CHIV InfectionsHomosexuality, MaleHumansIndiaMalePrevalenceSexual PartnersSubstance Abuse, IntravenousSurveys and Questionnaires

Identifiers

PMID29182638
PMCPMC5705124

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.